1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
James Li
James Li
Articles (705)  | Author's Website |

Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences

Former tiger cub keeps investing in biotech companies

January 11, 2019 | About:

Andreas Halvorsen (Trades, Portfolio), portfolio manager of Viking Global Investors L.P., disclosed this week a 38,341,357-share stake in Myovant Sciences Ltd. (NYSE:MYOV) for $16.41 per share, further expanding his exposure to the biotechnology industry.

The former protégé of Tiger Management founder Julian Robertson (Trades, Portfolio) manages approximately $26 billion in assets for his clients, with approximately $18 billion in equities. According to the fund’s website, Viking Global seeks long-term capital appreciation through a research-intensive, long-term-focused investment approach.

b51e5290-15bb-11e9-af9c-eddebb8aa23c.png

Viking Global’s equity portfolio contains approximately 20.13% weight in health care stocks, second only to the 26.25% weight in the consumer cyclical sector.

Company and industry background

Myovant Sciences, a clinical-stage biopharmaceutical company formed in February 2016, develops and commercializes innovative therapies for men’s and women’s health, including the treatment of advanced prostate cancer in men and endocrine diseases in women. The company’s product candidate is relugolix, an oral, once-daily supplement for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis.

GuruFocus ranks Myovant’s profitability 3 out of 10 as returns on equity underperform over 89% of global competitors. The company highlighted several risks and uncertainties in its June 2018 annual report, including its limited operating history and significant net losses stemming from high research and development costs, common risks that fledging biotech companies face. For the quarter ending Sept. 30, Myovant reported research and development expenses of $53.8 million, up approximately $29.6 million from third-quarter 2017. The sharp increase in expenses reflects ongoing clinical trials for relugolix and Myovant’s other key product, MVT-602.

Net losses for the quarter also reflect Myovant’s increased selling, general and administrative expenses, as well as interest expenses related to financing agreements with NovaQuest Pharma Opportunities Fund IV L.P. and Hercules Capital Inc.

Guru continues investing in biotech

According to GuruFocus real-time picks, a Premium feature, Halvorsen has invested in several other biotech companies since October, including aTyr Pharma Inc. (NASDAQ:LIFE), Urovant Sciences Ltd. (NASDAQ:UROV), Moderna Inc. (NASDAQ:MRNA) and Axovant Sciences Ltd. (AXON).

Disclosure: No positions.

Read more here:

About the author:

James Li
I am an editorial assistant and researcher at GuruFocus. I have a Master's in Finance from SMU, and I enjoy writing reports on financial trends and investor portfolios. Follow me on Twitter at @JamesLiGuru!

Visit James Li's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by James Li


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK